More sensitive techniques are required for the detection of low frequencies of malignant
cells during and after treatment, ie, detection of minimal residual disease (MRD). In order to …

Quantification of residual leukemic cells at early time points during therapy can reliably
predict the outcome in children with acute lymphoblastic leukemia (ALL). Recently …

Measurable/minimal residual disease (MRD) refers to the small number of malignant cells
remaining in the body of cancer patients during or after treatment. MRD detection is the best …

Early identification of patients at high risk of relapse is a major goal of current translational
research in oncohematology. Minimal residual disease (MRD) detection by polymerase …

The detection of minimal residual disease (MRD) represents a major goal in leukemias with
great potential applications: identification of patients at high risk of relapse, earlier detection …

Detection of minimal residual disease (MRD) has prognostic value in acute lymphoblastic
leukemia and acute myeloid leukemia. Particularly the evaluation of early treatment …

The clearance of malignant clonal cells significantly correlates with clinical outcomes in
many hematologic malignancies. Accurate and high throughput tools for minimal residual …

Monitoring minimal residual disease (MRD) is useful to evaluate therapeutic response and
risk of relapse in patients with hematologic malignancy. Currently available quantitative …

Modern treatment protocols lead to complete remission (CR) in a considerable proportion of
patients with lymphoproliferative disorders. However, many of these patients ultimately …